莫西沙星对清除早发医院获得性肺炎病原菌分析  

The remove pathogens of moxifloxacin in the treatment of early and no risk factory for MDR hospital-acquired pneumonia

作　　者：吴春玲[1,2] 楼翰健[1,2] 贾维[1,2] 陈国钟[1,2] 滕一鸣[1,2] 周旭玲[1,2] 宋秋香[1,2] 朱捍君[1,2] 吴亦[1,2] 何建新[1,2] 

机构地区：[1]温州医学院附属义乌医院 [2]浙江义乌市中心医院,义乌322000

出　　处：《海峡药学》2010年第8期138-139,共2页Strait Pharmaceutical Journal

基　　金：2008年浙江省医学会临床科研基金项目

摘　　要：目的观察莫西沙星对清除早发医院获得性肺炎病原菌的作用。方法选取早发且无多重耐药危险因素的医院获得性肺炎患者60例,随机分为两组,莫西沙星组30例,予盐酸莫西沙星氯化钠注射液(莫西沙星0.4g加入0.9%氯化钠注射液250mL中)静脉滴注,1日1次,连用7d,头孢曲松组30例,予头孢曲松钠针剂2.0g加入0.9%氯化钠注射液250mL中静脉滴注,1日1次,连用7d,观察病原菌清除率。结果治疗后病原菌清除率莫西沙星组优于头孢曲松组,差异显著(P<0.05)。结论莫西沙星针剂治疗早发且无多重耐药危险因素的医院获得性肺炎具有较好的病原菌清除率,是较理想的药物之一。OBJECTIVE To study the remove pathogens of moxifloxacin in the treatment of early and no risk factory for MDR hospital-acquired pneumonia. METHODS 60 cases of early and no risk factory for MDR hospital-acquired pneumonia were randomly divided into moxifloxacin（400mg ivgtt qd for 7d）treatment group（30 cases） and ceftriaxone（2.0g ivgtt qd for 7d）treatment group（30 cases）, observation clearance of pathogens. RESULTS After treatment, the clearance of pathogens in moxifloxacin treatment group is superior to ceftriaxone group（P 〈0.05）.CONCLUSION Moxifloxacin injection treatment of early and no risk factory for MDR hospital-acquired pneumonia have a better clearance rate of pathogens, is one of the ideal drug.

关 键 词：莫西沙星 早发 医院获得性肺炎 病原菌 

分 类 号：R969.4[医药卫生—药理学]